Breakthrough in Neuropsychiatry: Stabilized D-Cycloserine the Future of TMS Augmentation with the CMIO of NRx Pharmaceuticals
Thursday, April 16, 2026
12:00 PM – 1:00 PM ET
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), recently reported a major formulation breakthrough with a newly developed, chemically stabilized, sustained-release version of D-cycloserine (DCS) – a well-characterized NMDA receptor modulator with the potential to significantly enhance neuroplasticity and treatment response in depression.
Historically, D-cycloserine has demonstrated the ability to meaningfully improve outcomes when combined with Transcranial Magnetic Stimulation (TMS), with prior studies suggesting an up to 2x increase in response rates and an 8x increase in remission versus TMS alone. However, inconsistent pharmacokinetics and limited stability have constrained its clinical utility. NRx’s novel formulation is designed to overcome these limitations by delivering sustained exposure aligned with therapeutic intervention windows, potentially unlocking a more reliable and scalable treatment paradigm.
Join Jason Kolbert, Head of Research at D. Boral Capital and Prof. Joshua Brown, MD, PhD, CMIO of NRx Pharmaceuticals, to learn more about the clinical relevance of DCS in modern psychiatric care, the implications of improved formulation stability, and how this approach could fit within evolving treatment frameworks that include TMS, ketamine, and other rapid-acting antidepressants. We will also explore the potential for integration with NRx’s expanding clinic model and the broader commercial opportunity in treatment-resistant depression.
Register now to access an in-depth discussion on rapid innovation and the evolving standard of care in neuropsychiatric treatment.